Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
About this study
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
- Condition
- Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Sponsor
- Kyowa Kirin, Inc.
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Adults ≥18 years of age with either CTCL or ATLL;
- AlloHCT performed from January 2012 onward.
Exclusion 1
- Patients without consent for research.
Where
1 site, 1 recruiting
CIBMTR
Milwaukee, Wisconsin, United States
Contact
-
Linda J Burns, MD
414-805-0714 lburns@mcw.edu
-
Jatin Jadwani, BDS, MSc Clinical Research
+49 15114861167 jatin.jadwani@kyowakirin.com
Potential match only. Final eligibility is determined by the study team.